R&D Support and Predictive Studies

Safer technical decisions from the start of development

Predictive evaluations and toxicological analyses that guide decisions according to the toxicological profile of the formulation on a scientific basis, optimizing resources and avoiding unnecessary studies.

The cost of moving forward without predictability

Formulations that move on to expensive laboratory studies without prior screening lead to rework, delays in the pipeline and budget overruns.

Without predictive evaluation, the risk of failing at advanced stages jeopardizes schedules and the regulatory team's confidence with the board.

R&D teams that rely exclusively on laboratory tests lose competitive agility when compared to competitors who already use computer modeling and in-silico tools.

How SmartTox solves this

We integrate predictive science into your R&D process so that every technical decision has a solid foundation before it reaches the laboratory. With models validated according to OECD guidelines and direct alignment with RDC 294/2019, our team, led by experts with more than 20 years' experience in regulatory toxicology, delivers opinions that reduce costs, speed up timelines and increase the likelihood of approval.

Detailed services

Theoretical Toxicological Screening:

Preliminary analysis of the toxicological profile using validated databases and computer models. We identify structural alerts and critical endpoints before investing in studies, allowing us to select formulations with a higher probability of regulatory approval.

QSAR / SAR:

Quantitative and qualitative modeling of structure-activity relationships to predict toxicity, biodegradability and regulatory endpoints. As required by RDC 294/2019 for the evaluation of impurities and metabolites, our models meet OECD validation criteria and are accepted by regulatory authorities worldwide.

Toxicological pre-classification:

Preliminary hazard classification according to GHS/ANVISA/RDC 294 criteria, allowing the toxicological category to be anticipated and strategic decisions on formulation, packaging and labeling to be made prior to the registration protocol.

Evaluation of the Most Toxic:

Identification of the most toxic component in the qualitative and quantitative composition, according to Article 47 of RDC 294/2019. Fundamental analysis for the rational selection of formulations and the toxicological classification strategy of the final product.

Structure and Activity Technical Report:

Technical-scientific opinions based on the structure-activity relationship, based on in-silico data and robust scientific literature. An intelligent strategy to justify dispensing with unnecessary studies, in accordance with Annex III of RDC 294/2019, generating real savings for your company.

Why SmartTox

QSAR models validated according to OECD guidelines.

Scientific team with over 20 years' experience (Master's in Toxicology, USP).

Direct alignment with the requirements of RDC 294/2019.

Proven cost savings in laboratory studies.

Co-authors of the OPEX Calculator, a reference tool for occupational risk assessment